

Francesca Pregnolato

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7455886/francesca-pregnolato-publications-by-year.pdf>
Version: 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43 papers	1,050 citations	19 h-index	32 g-index
46 ext. papers	1,345 ext. citations	6.6 avg, IF	3.86 L-index

#	Paper	IF	Citations
43	Hyaluronic Acid Therapy in Hip OA Does Not Perform Equally in Osteoarthritis Secondary to Juvenile Idiopathic Arthritis When Compared to Primary Osteoarthritis: A 2-Year Preliminary Evaluation.. <i>Advances in Therapy</i> , 2022 , 39, 1267	4.1	
42	Tumor Necrosis Factor- α Inhibition Before and After Rituximab Treatment in Juvenile Idiopathic Arthritis: What Shall We Expect? A Pilot Study.. <i>Journal of Rheumatology</i> , 2022 ,	4.1	
41	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021 , 60, 1114-1124	3.9	19
40	Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103377	7	1
39	Comment on: EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies: reply. <i>Rheumatology</i> , 2021 , 60, e110-e112	3.9	
38	Exosome microRNAs in Amyotrophic Lateral Sclerosis: A Pilot Study. <i>Biomolecules</i> , 2021 , 11,	5.9	2
37	Nonpegylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020 , 38, 478-486	1.3	6
36	Hyaluronic Acid Injections in the Treatment of Osteoarthritis Secondary to Primary Inflammatory Rheumatic Diseases: A Systematic Review and Qualitative Synthesis. <i>Advances in Therapy</i> , 2020 , 37, 1347-1359	4.1	11
35	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020 , 19, 102509	13.6	8
34	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102525	13.6	13
33	Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled	2.4	3
32	Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome 2020 ,		8
31	Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. <i>Neurobiology of Disease</i> , 2020 , 145, 105051	7.5	18
30	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020 , 11, 584241	8.4	86
29	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019 , 10, 773	8.4	14
28	Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1764-1769	5.9	11
27	Effectiveness and Tolerability of Repeated Courses of Viscosupplementation in Symptomatic Hip Osteoarthritis: A Retrospective Observational Cohort Study of High Molecular Weight Medium Molecular Weight Hyaluronic Acid No Viscosupplementation. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1007	5.6	8

26	New insight into antiphospholipid syndrome: antibodies to β glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019 , 104, 819-826	6.6	21
25	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. <i>Analytical Biochemistry</i> , 2019 , 566, 133-138	3.1	5
24	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e50	2.4	15
23	Beyond thrombosis: Anti- β GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018 , 90, 76-83	15.5	41
22	Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1426-1431	2.4	25
21	Diagnostic specificity of autoantibodies to M-type phospholipase A2 receptor (PLA2R) in differentiating idiopathic membranous nephropathy (IMN) from secondary forms and other glomerular diseases. <i>Journal of Nephrology</i> , 2018 , 31, 271-278	4.8	33
20	Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH). <i>European Journal of Endocrinology</i> , 2018 , 178, 23-32	6.5	54
19	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018 , 93, 114-123	15.5	13
18	Taurine Administration Recovers Motor and Learning Deficits in an Angelman Syndrome Mouse Model. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	8
17	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018 , 17, 1153-1168	13.6	43
16	Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). <i>Autoimmunity Reviews</i> , 2016 , 15, 146-54	13.6	54
15	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2016 , 7, 5	8.4	22
14	Measuring IgA Anti- β -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016 , 11, e0156407	3.7	50
13	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. <i>Arthritis Care and Research</i> , 2016 , 68, 432-9	4.7	57
12	Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2196-204	9.5	68
11	Phospholipid Autoantibodies (Nonanticardiolipin)-Antiprothrombin Antibodies 2014 , 741-749		1
10	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 730-7	5.3	8
9	A non-complement-fixing antibody to β glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , 2014 , 123, 3478-87	2.2	98

8	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. <i>Immunologic Research</i> , 2013 , 56, 432-8	4.3	43
7	A5.5 Antibodies against Domain I of β Glycoprotein I in Antiphospholipid Antibody Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A31.3-A32	2.4	
6	Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the β glycoprotein I phospholipid-binding site. Implications for human fetal loss. <i>Journal of Autoimmunity</i> , 2012 , 38, J209-15	15.5	47
5	Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R271	5.7	32
4	Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1388-92	2.4	15
3	Obstetric and vascular APS: same autoantibodies but different diseases?. <i>Lupus</i> , 2012 , 21, 708-10	2.6	34
2	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 213-23	3.8	9
1	Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?. <i>Journal of Autoimmunity</i> , 2008 , 30, 51-7	15.5	44